RUNX/AML and C/EBP factors regulate CD11a integrin expression in myeloid cells through overlapping regulatory elements.
Open accessThe DOI matches its Crossref record; 61 of the 63 references it cites were found in a registry or an index; 4 of the 26 sources its claims cite were checked for support.
Abstract
The CD11a/CD18 (leukocyte function-associated antigen 1 [LFA-1]) integrin mediates critical leukocyte adhesive interactions during immune and inflammatory responses. The CD11a promoter directs CD11a/CD18 integrin expression, and its activity in lymphoid cells depends on a functional RUNX1/AML-1–binding site (AML-110) within the MS7 sequence. We now report that MS7 contains a C/EBP-binding site (C/EBP-100), which overlaps with AML-110 and is bound by C/EBP factors in myeloid cells. C/EBP and RUNX/AML factors compete for binding to their respective cognate elements and bind to the CD11a promoter MS7 sequence in a cell lineage- and differentiation-dependent manner. In myeloid cells MS7 is primarily recognized by C/EBP factors in proliferating cells whereas RUNX/AML factors (especially RUNX3/AML-2) bind to MS7 in differentiated cells. RUNX3/AML-2 binding to the CD11a promoter correlates with increased RUNX3/AML-2 protein levels and enhanced CD11a/CD18 cell surface expression. The relevance of the AML-110 element is underscored by the ability of AML-1/ETO to inhibit CD11a promoter activity, thus explaining the low CD11a/CD18 expression in t(8;21)–containing myeloid leukemia cells. Therefore, the expression of the CD11a/CD18 integrin in myeloid cells is determined through the differential occupancy of the CD11a proximal promoter by transcription factors implicated in the pathogenesis of myeloid leukemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 Valid · 0 Not valid · 11 Not checked · 88 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“its activity in lymphoid cells depends on a functional RUNX1/AML-1-binding site (AML-110) within the MS7 sequence.”
- Also stated in: § Introduction · p. 1 · plain
“The RUNX1/AML-1 transcription factor contributes to the tissuespecific activity of the CD11a promoter in lymphoid cells through recognition of the AML-110 element, 11”
What the sources say
- Supportedcites [11] 11. Puig-Kro ¨ger A, Lo ´ pez-Rodrı ´guez C, Relloso M, et al. Polyomavirus enhancer-binding protein 2/core binding factor/acute myeloid leukemia factors contribute to the cell type-specific activity of the CD11a integrin gene promoter. J Biol Chem. 2000;275:28507-28512. source
The RESULTS (p. 2-3) define the AML-110 complex as the specific retarded complex formed on the MS7 probe (-120/-88) with Jurkat T-cell and JY B-lymphoblastoid nuclear extracts, dependent on the sequence (-110)5'-CCCTGCGGTTTC-3' within MS7, and the PROMOTER ACTIVITY section (p. 3-4) shows this site is recognized by PEBP2/CBF/AML1 (RUNX1/AML-1) factors. The same sections (p. 3, Fig. 3; p. 1 abstract) report that mutating CD11a-110 cut promoter activity to 30% in Jurkat lymphoid cells, stating the element 'is required for an optimal activity of the CD11a gene promoter' — the cell type-specific effect being much weaker in K562 and HepG2. The only mild divergence is nomenclature/strength: the paper names the element CD11a-110 and the bound complex AML-110, and describes an ~70% (not total) loss of activity, consistent with the claim's 'requires ... for its activity'. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Introduction · p. 1 · plain
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“RUNX 𝛂 subunits are synthesized and proteolytically degraded in the cytoplasm unless associated to CBF𝛃 . 50”
What the sources say
- Partly supportedcites [50] sourceExperimental — accuracy not yet measured
The Results report that PEBP2β stabilizes RUNX1 and also stabilizes RUNX2 and RUNX3. But the Introduction describes RUNX proteins as nuclear and PEBP2β as mainly cytoplasmic; the Discussion suggests their dimerization may occur in the nucleus. The paper therefore does not support the claim that RUNXα subunits are degraded in the cytoplasm. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“As described, 40,45 C/EBP 𝛂 42 disappeared at the final stages of myeloid differentiation (Figure 8B).”
What the sources say
- Partly supportedcites [40] sourceExperimental — accuracy not yet measured
The only passage in our copy addressing this is in 'A Lesson from Life' (C/EBP Isoforms Coordinate the Differentiation and Function of Myelomonocytic Cells), which states that in vivo C/EBPα expression is relatively high in immature granulocytic cells but is down-regulated in most mature granulocytes — and it credits that observation to its reference 65. This supports the direction of the claim (loss of C/EBPα at late granulocytic maturation) but not its specifics: our copy nowhere names the 42-kDa C/EBPα isoform (it mentions only in general terms, in 'Interactions with Other Transcription Factors', that C/EBPα and C/EBPβ mRNAs can give rise to truncated forms), it says 'down-regulated in most mature granulocytes' rather than disappearance, and it restricts the statement to the granulocytic branch rather than myeloid differentiation as a whole (the same section notes C/EBPβ determining terminal differentiation of macrophages). (LLM, conf=0.72)
- Not checked yetcites [45] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These 2 apparently contradictory results could be reconciled when considering the existence of RUNX and C/EBP isoforms, which differ in transcriptional potency and even act as repressors (AML1 𝛅 N, C/EBP 𝛂 30). 40,59”
What the sources say
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“RUNX factors were the only MS7-binding factors in both T (Jurkat and tumor-infiltrating lymphocytes) and B lymphoid (JY, Ramos, Raji) lineages (Figure 1B)”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
65 more claims
Create a free account to see all 103 claims and to verify the 22 references still open.
- It may state two separate claims as one. 26
- The quote only partly states this claim. 4
- Probably not a substantial claim. 6
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“(RUNX factors alone are relatively weak activators of transcription.4,5,7,8,11)”
From RUNX1 regulates corepressor interactions of PU.1 (2011) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“In keeping with this paradigm, RUNX1 alone is a relatively weak activator of transcription.4,5,7,8,11”
From RUNX1 regulates corepressor interactions of PU.1 (2011) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“RUNX1 by itself is a weak activator of transcription”
From Runx1 regulation of Pu.1 corepressor/coactivator exchange identifies specific molecular targets for leukemia differentiation therapy (2014) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Discussion · p. 9
“However, because AML-1/ETO down-regulates C/EBP 𝛂 expression, 55”
§ Acknowledgments · p. 10
“54. Pabst T, Mueller BU, Harakawa N, et al. AML1ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med. 2001;7:444-451. 55. Brouwer RE, Zwinderman KH, Kluin-Nelemans HC, van Luxemburg-Heijs SA, Willemze R, Falkenburg JH. Expression and induction of costimulatory and adhesion molecules on acute myeloid leukemic cells: implications for adoptive immunotherapy. Exp Hematol. 2000;28:161-168.”
Citations
Cites
Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm
Springer, T. A. (1994) · Cell · doi:10.1016/0092-8674(94)90337-9 · Cited by 6,929
Schreiber, E., Matthias, P., Müller, M. M., & Schaffner, W. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.15.6419 · Cited by 4,179
Okuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., & Downing, J. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80986-1 · Cited by 1,856
Wang, Q., Stacy, T., Binder, M., Marin-Padilla, M., Sharpe, A. H., & Speck, N. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3444 · Cited by 1,178
Causal Relationship between the Loss of RUNX3 Expression and Gastric Cancer
Li, Q.-L., Ito, K., Sakakura, C., Fukamachi, H., Inoue, K.-I., Chi, X.-Z., Lee, K.-Y., Nomura, S., Lee, C.-W., Han, S.-B., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00690-6 · Cited by 1,028
Impaired Energy Homeostasis in C/EBPα Knockout Mice
Wang, N.-D., Finegold, M. J., Bradley, A., Ou, C. N., Abdelsayed, S. V., Wilde, M. D., Taylor, L. R., Wilson, D. R., & Darlington, G. J. (1995) · Science · doi:10.1126/science.7652557 · Cited by 929
Zhang, D.-E., Zhang, P., Wang, N.-D., Hetherington, C. J., Darlington, G. J., & Tenen, D. G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.569 · Cited by 910
Pabst, T., Mueller, B. U., Zhang, P., Radomska, H. S., Narravula, S., Schnittger, S., Behre, G., Hiddemann, W., & Tenen, D. G. (2001) · Nature Genetics · doi:10.1038/85820 · Cited by 901
Biological Role of the CCAAT/Enhancer-binding Protein Family of Transcription Factors
Lekstrom-Himes, J., & Xanthopoulos, K. G. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.44.28545 · Cited by 801
Transcription Factors, Normal Myeloid Development, and Leukemia
Tenen, D. G., Hromas, R., Licht, J. D., & Zhang, D.-E. (1997) · Blood · doi:10.1182/blood.v90.2.489 · Cited by 735
Cited by
Stein, G. S., Lian, J. B., Wijnen, A. J. V., Stein, J. L., Montecino, M., Javed, A., Zaidi, S. K., Young, D. W., Choi, J.-Y., & Pockwinse, S. M. (2004) · Oncogene · doi:10.1038/sj.onc.1207676 · Cited by 538
“…motifs are necessary, but not sufficient, for transcriptional activation, suggesting that Runx2 promoter elements support the assembly of regulatory complexes that render target genes poised but not completely competent for the onset of expression (Javed et al., 1999; Puig-Kroger et al., 2003).”
BackgroundEdgar, L., Akbar, N., Braithwaite, A. T., Krausgruber, T., Gallart-Ayala, H., Bailey, J., Corbin, A. L., Khoyratty, T. E., Chai, J. T., Alkhalil, M., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.046464 · Cited by 340
Fainaru, O., Woolf, E., Lotem, J., Yarmus, M., Brenner, O., Goldenberg, D., Negreanu, V., Bernstein, Y., Levanon, D., Jung, S., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600085 · Cited by 289
“…expression pattern of b2-integrins in Runx3 KO DC The implication of RUNX3 in the regulation of lymphoid- and myeloid-specific activity of the CD11a promoter (Puig-Kroger et al, 2003 and references therein) led us to test whether Runx3 deficiency affects DC b2-integrin expression.”
BackgroundSelf-citationCore-binding factors in hematopoiesis and immune function
de Bruijn, M. F., & Speck, N. A. (2004) · Oncogene · doi:10.1038/sj.onc.1207763 · Cited by 231
“…2001; Telfer and Rothenberg, 2001; Basecke et al., 2002; Kundu et al., 2002; Taniuchi et al., 2002; Zhao et al., 2002; Bjerregaard et al., 2003; Ehlers et al., 2003; Elagib et al., 2003; Puig-Kroger et al., 2003; Woolf et al., 2003; Fainaru et al., 2004; Lorsbach et al., 2004; North et al., 2004).”
BackgroundEpigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis
Ciavatta, D. J., Yang, J., Preston, G. A., Badhwar, A. K., Xiao, H., Hewins, P., Nester, C. M., Pendergraft, W. F., Magnuson, T. R., Jennette, J. C., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40034 · Cited by 210
Metadata
- Authors
- Puig-Kröger, A., Sánchez-Elsner, T., Ruiz, N., Andreu, E. J., Prosper, F., Jensen, U. B., Gil, J., Erickson, P., Drabkin, H., Groner, Y., & Corbí, A. L.
- Affiliations
- From the Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Cientificas, Madrid, Spain; Clínica Universitaria, Universidad de Navarra, Spain; Institute of Human Genetics, Aarhus, Denmark; Hospital Universitario Gregorio Marañón, Madrid, Spain; University of Colorado Health Sciences Center, Denver; and Department of Molecular Genetics, The Weizmann Institute of Science, Rehovot, Israel.
- Consejo Superior de Investigaciones Científicas (ES)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2003-11-01
- Volume
- 102
- Issue
- 9
- Pages
- 3252-3261
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2169387418
- Semantic Scholar
- 06ba323399f1d61498212e10533784ec1342d8c5
- Cited by
- 51
- References
- 63
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 1 · 2022: 1 · 2021: 3 · 2019: 2 · 2017: 3 · 2016: 2 · 2015: 2 · 2014: 4 · 2013: 2 · 2012: 3
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Deposito Adademico Digital Universidad De Navarra (University of Navarra) (submittedVersion, other-oa)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- Topics
- Health Sciences › Medicine › Immunology and Allergy › Cell Adhesion Molecules Research
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- LFA-1, myeloid differentiation, integrin expression regulation
- MeSH terms
- Binding Sites, DNA-Binding Proteins, Gene Expression Regulation, Genes, Regulator, Humans, Leukemia, Myeloid, Promoter Regions, Genetic, Proto-Oncogene Proteins, Repressor Proteins, Transcription Factors, Myeloid Cells, CCAAT-Enhancer-Binding Proteins, CD11a Antigen, Cell Line, Tumor, Core Binding Factor Alpha 2 Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RUNX/AML and C/EBP factors regulate CD11a integrin expression in myeloid cells through overlapping regulatory elements. https://app.cochat.ai/papers/10.1182/blood-2003-02-0618
- The paper
- Puig-Kröger, A., Sánchez-Elsner, T., Ruiz, N., Andreu, E. J., Prosper, F., Jensen, U. B., Gil, J., Erickson, P., Drabkin, H., Groner, Y., & Corbí, A. L. (2003). RUNX/AML and C/EBP factors regulate CD11a integrin expression in myeloid cells through overlapping regulatory elements. Blood. https://doi.org/10.1182/blood-2003-02-0618
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.